Article Highlights
Updates every hour. Last Updated: 21-Aug-2025 15:11 ET (21-Aug-2025 19:11 GMT/UTC)
SlTOR negatively regulates cold stress responses
Nanjing Agricultural University The Academy of SciencePlants often face a trade-off between growing and surviving under stress. In this study, researchers uncovered how the target of rapamycin (TOR) kinase in tomatoes plays a central role in navigating this balance.
- Journal
- Horticulture Research
Engineered vesicles emerge as a promising drug delivery system in antiviral therapy
Shanghai Jiao Tong University Journal CenterAkkermansia muciniphila (Akk) has gained significant attention for its role in regulating metabolic health and its impact on diseases such as cancer, diabetes, obesity, and inflammatory bowel disease (IBD). Studies suggest that the regulatory effects of Akk are primarily realized through its secreted extracellular vesicles (Akk-EVs), rather than relying solely on the in vivo form. These highly stable bilayer vesicles can regulate physiological and pathological processes in host cells through local or systemic signaling. Unlike direct delivery by live bacteria, Akk-EVs can efficiently deliver a variety of bioactive molecules involved in the regulation of glucose metabolism, lipid homeostasis, intestinal immunity, and maintenance of intestinal barrier integrity without the risk of infection. Given that natural and engineered EVs are increasingly entering clinical trials, Akk-EVs, with their superior stability and specificity, present a promising therapeutic alternative to live bacterial treatments. This review summarizes the regulatory mechanisms of Akk-EVs in health and disease and discusses their potential applications in precision medicine and clinical therapy, offering new insights into therapeutic strategies for metabolic disorders, cancer, and gut diseases.
- Journal
- LabMed Discovery
Advances in von Willebrand disease diagnosis
Shanghai Jiao Tong University Journal CenterVon Willebrand disease (VWD) is caused by a quantitative or qualitative defect of von Willebrand factor (VWF). Despite its prevalence as the most common hereditary bleeding disorder and the associated morbidity, its diagnosis and classification remains a challenge. This is mainly attributed to the heterogeneity of the disorder, multi-faceted functions of VWF, limitations of diagnostic assays, and significant impacts of various patho-physiological processes on VWF. For the past few years, significant progress has been made in elucidating the structural basis of VWF activation and development of VWF activity assays. The O-glycosylated sequences flanking the VWF A1 domain constitute a discontinuous and force-sensitive autoinhibitory module (AIM), which regulates the VWF affinity for GPIbα. New options for laboratory assessment of VWF activity include VWF∶GPIbM and VWF∶GPIbNab. The former utilizes a recombinant gain-of-function GPIbα fragment that supports spontaneous binding to plasma VWF, with less variability and higher precision compared to the traditional ristocetin cofactor activity assay. The latter utilizes a VWF-activating nanobody targeting the AIM to activate VWF, demonstrating the highest sensitivity for high-molecular-weight multimers among contemporary assays in the preliminary study. In this review, we focused on recent developments in the field of VWD diagnosis and considered how these advances can improve diagnostic algorithms and patient care in clinical practice.
- Journal
- LabMed Discovery
Drought-proof apples? new sugar transport genes make it possible
Nanjing Agricultural University The Academy of ScienceNew research reveals that certain sugar transporter genes in apples play a key role in boosting drought resistance while enhancing sugar accumulation.
- Journal
- Horticulture Research
A molecular makeover: histone switches drive salt tolerance in peas
Nanjing Agricultural University The Academy of ScienceA new study has decoded how pea plants respond to salt stress through precise epigenetic reprogramming.
- Journal
- Horticulture Research
Breakthrough in cancer therapy: targeting mutant p53 with novel inhibitors shows promise
FAR Publishing LimitedA comprehensive review by researchers at Taylor’s University highlights the oncogenic role of mutant p53 (mutp53) in cancer progression and resistance to therapy. The study explores preclinical and clinical advancements in mutp53-targeting compounds, with APR-246 leading the charge in Phase III trials. These inhibitors aim to restore wild-type p53 function, offering new hope for precision cancer treatment.
- Journal
- Current Molecular Pharmacology
TNFα signaling at the crossroads of cancer: unveiling dual roles in tumor progression and therapy
FAR Publishing LimitedA groundbreaking review in Current Molecular Pharmacology explores the dual roles of Tumor Necrosis Factor-alpha (TNFα) in cancer. Led by Sonal M. Manohar, the study highlights TNFα's complex signaling pathways—activating both pro-survival (NF-κB) and pro-death (apoptosis/necroptosis) mechanisms—and its potential as a therapeutic target. "Understanding TNFα's context-dependent actions is key to unlocking its anticancer potential," said Manohar.
- Journal
- Current Molecular Pharmacology
Fangchinoline from traditional Chinese medicine targets T cells in Sjögren’s syndrome, inducing apoptosis via oxidative stress and Akt inhibition
FAR Publishing LimitedA study led by Yubo Xu at Tongji University reveals that Fangchinoline (Fan), a compound from Stephania tetrandra, triggers oxidative stress-induced DNA damage and apoptosis in Jurkat T cells while inhibiting Akt signaling. This dual mechanism highlights Fan’s potential as a therapeutic agent for Sjögren’s syndrome (SS), where T cell infiltration drives disease progression.
- Journal
- Current Molecular Pharmacology
Breakthrough review unveils molecular mechanisms and emerging therapies for sarcopenia in aging populations
FAR Publishing LimitedA comprehensive review in Current Molecular Pharmacology explores sarcopenia’s molecular pathways and cutting-edge interventions. Led by Priyanka Prajapati and team, the study highlights oxidative stress, mitochondrial dysfunction, and promising treatments like exercise, nutraceuticals, and hormone therapy. "Targeting these pathways could revolutionize sarcopenia management," said Prajapati.
- Journal
- Current Molecular Pharmacology